Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lombard Medical Technologies, a cardiovascular device and polymer coatings company, has received Russian approval for its Aorfix, which is indicated for the treatment of abdominal aortic aneurysms.
Subscribe to our email newsletter
According to the company, data from a four-year post-implantation multi-center European study, performed in Greece, Poland and Austria, showed that Aorfix provides significant annual shrinkage (8% to 16%) of the aneurysm sac with no migration of the device.
To date, Aorfix has been successfully implanted into two patients and a further 15 implants are expected before the end of 2008, the company said.
Brian Howlett, CEO of Lombard Medical, said: “We are extremely pleased with the feedback received on Aorfix at the Veith Symposium, confirming the widely held view amongst clinicians that Aorfix is a versatile device which can be deployed in both routine and complex anatomies. It is also pleasing to obtain approval for Aorfix in Russia which is a growing market and will significantly increase the sales potential for Aorfix.”